Safety of SARS-CoV-2 vaccines in patients with chronic myeloid leukemia: a multicenter survey in China

Affiliations

• ¹ Department of Hematology, Institute of Hematology, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China.
• ² Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Henan Provincial Tumor Hospital, Zhengzhou, Henan 450000, China.
• ³ Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100000, China.
• ⁴ Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430000, China.
• ⁵ Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430000, China.
• ⁶ Department of Leukemia, National Clinical Research Center for Blood Disease, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin 300020, China.
• ⁷ Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510000, China.
• ⁸ Department of Leukemia, Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 201100, China.
• ⁹ Department of Hematology, Xijing Hospital, Air Force Medical University of PLA, Xi'an, Shaanxi 710000, China.